TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23562198

Group type: EXPERIMENTAL
Intervention: TAA HFA at 14, 110, or 440 micrograms once daily
Number of subjects: 780

Group type: EXPERIMENTAL
Intervention: TAA CFC at 14, 110, or 440 micrograms once daily
Number of subjects: 780

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 780

Group type: EXPERIMENTAL
Intervention: TAA HFA and TAA CFC formulations
Number of subjects: 780

Group type: EXPERIMENTAL
Intervention: TAA HFA at 7 micrograms per nostril once daily
Number of subjects: 780
Study: 20976495

Group type: EXPERIMENTAL
Intervention: Tacker fixation (group I)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Suture fixation (group II)
Number of subjects: 68
Study: 19135348

Group type: EXPERIMENTAL
Intervention: MK‐0359 (15mg/day)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 17174015

Group type: EXPERIMENTAL
Intervention: High dose selenium (Se+ group, 474, 316, 158 microg/day for 3 days followed by 31.6 microg/day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: High dose selenium (Se+ group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (Se- group, standard dose of 31.6 microg/day)
Number of subjects: 40
Study: 15143088

Group type: EXPERIMENTAL
Intervention: Dalteparin (5,000 IU, once-daily subcutaneous injection)
Number of subjects: 385

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Dalteparin (in subgroup of better prognosis patients, n = 55)
Number of subjects: 385

Group type: COMPARATOR
Intervention: Placebo (in subgroup of better prognosis patients, n = 47)
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Dalteparin
Number of subjects: 385
Study: 11359050

Group type: EXPERIMENTAL
Intervention: Fluoride slow-releasing glass devices
Number of subjects: 174
Study: 9263773

Group type: EXPERIMENTAL
Intervention: Ulm sample
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Upper Swabia isolate
Number of subjects: 2
Study: 2070868

Group type: EXPERIMENTAL
Intervention: Intrauterine insemination (IUI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cervical cap with whole ejaculate or coitus
Number of subjects: 0
Study: 6660454

Group type: EXPERIMENTAL
Intervention: Althesin
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Thiopentone
Number of subjects: 80
Study: 30669521

Group type: EXPERIMENTAL
Intervention: Growing Up Milk-Lite (GUMLi)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Cow's Milk (CM)
Number of subjects: 83
Study: 29499060

Group type: COMPARATOR
Intervention: Standard of Care (SoC) TB and HIV testing
Number of subjects: 3012

Group type: EXPERIMENTAL
Intervention: Point of Care CD4 (PoC CD4)
Number of subjects: 3012

Group type: EXPERIMENTAL
Intervention: Point of Care CD4 + Household Isoniazid Preventive Therapy (HH-IPT)
Number of subjects: 3012
Study: 26927166

Group type: EXPERIMENTAL
Intervention: CHO + WP (20 g whey protein isolate)
Number of subjects: 10

Group type: COMPARATOR
Intervention: CHO (carbohydrate-rich breakfast without whey protein)
Number of subjects: 10

Group type: COMPARATOR
Intervention: NB (breakfast omitted)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CHO + WP
Number of subjects: 10

Group type: COMPARATOR
Intervention: CHO + WP, CHO, NB
Number of subjects: 10
Study: 24418941

Group type: EXPERIMENTAL
Intervention: Continuous tranexamic acid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Discontinuous tranexamic acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no tranexamic acid)
Number of subjects: 0
Study: 23059926

Group type: EXPERIMENTAL
Intervention: Personalised Motivational Intervention (PMI)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Control group (brief health information)
Number of subjects: 218
Study: 19903626

Group type: EXPERIMENTAL
Intervention: SockIt! Oral Pain Gel applied to dentures
Number of subjects: 44

Group type: COMPARATOR
Intervention: No topical treatment
Number of subjects: 44
Study: 17467426

Group type: EXPERIMENTAL
Intervention: Carboplatin-paclitaxel (n = 19)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Carboplatin-docetaxel (n = 22)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Overall (both groups)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Major response group (persistent N2 disease)
Number of subjects: 41
Study: 15965070

Group type: EXPERIMENTAL
Intervention: 1-week intensive resistance training regimen in weightlifters
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (non-athletic individuals)
Number of subjects: 36
Study: 12090613

Group type: EXPERIMENTAL
Intervention: Neutral TV program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Violent TV program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sexually explicit TV program
Number of subjects: 0
Study: 9859725

Group type: EXPERIMENTAL
Intervention: Appital
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 7890241

Group type: EXPERIMENTAL
Intervention: Faecal alpha 1‐antitrypsin test
Number of subjects: 179

Group type: COMPARATOR
Intervention: Guaiac occult blood test
Number of subjects: 179
Study: 2311145

Group type: EXPERIMENTAL
Intervention: Epidural epinephrine (5 micrograms.ml‐1) added to bupivacaine (0.75 per cent)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Plain epidural bupivacaine (0.75 per cent)
Number of subjects: 20
Study: 6770801

Group type: EXPERIMENTAL
Intervention: 500 mg of sustained-release capsules once a day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 500 mg of capsules twice a day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 250 mg of tablets four times a day
Number of subjects: 0

Group type: COMPARATOR
Intervention: none
Number of subjects: 0
Study: 31429912

Group type: EXPERIMENTAL
Intervention: Web-based memory training
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Classroom-based memory training
Number of subjects: 208

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 208
Study: 31393742

Group type: EXPERIMENTAL
Intervention: Multi-component nurse-led lifestyle intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 28816142

Group type: EXPERIMENTAL
Intervention: Vorinostat 400 mg orally once daily for 14 days with concurrent stereotactic radiosurgery (SRS)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Vorinostat 200 mg and 300 mg doses
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS)
Number of subjects: 17
Study: 26347184

Group type: EXPERIMENTAL
Intervention: Entacapone with levodopa/benserazide (LB)
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Entacapone with levodopa/carbidopa (LC)
Number of subjects: 551

Group type: COMPARATOR
Intervention: Entacapone (LB and LC users)
Number of subjects: 551
Study: 24235824

Group type: EXPERIMENTAL
Intervention: Home-based pulmonary rehabilitation (HBPR) program with aerobic and muscle strength exercises
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (CG) with instructions for breathing and stretching exercises
Number of subjects: 0
Study: 22166188

Group type: EXPERIMENTAL
Intervention: Mediterranean-type (MED) diet
Number of subjects: 135

Group type: COMPARATOR
Intervention: Low-fat American Heart Association-type diet
Number of subjects: 135
Study: 19358791

Group type: EXPERIMENTAL
Intervention: Quetiapine XR 150 mg/day
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Quetiapine XR 300 mg/day
Number of subjects: 493

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 493
Study: 17536222

Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Desloratadine (5 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Montelukast vs Desloratadine
Number of subjects: 15
Study: 15028938

Group type: EXPERIMENTAL
Intervention: 5 mL acetic acid gel, intravaginally twice daily for 7 days
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo gel, intravaginally twice daily for 7 days
Number of subjects: 44
Study: 11573636

Group type: EXPERIMENTAL
Intervention: Tramadol 2 mg kg(-1) i.v.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: COMPARATOR
Intervention: Tramadol 2 mg kg(-1) i.v. and Placebo
Number of subjects: 80
Study: 9596551

Group type: EXPERIMENTAL
Intervention: Diclofenac50/misoprostol
Number of subjects: 1824

Group type: EXPERIMENTAL
Intervention: Diclofenac75/misoprostol
Number of subjects: 1824
Study: 7887134

Group type: EXPERIMENTAL
Intervention: NADH, 25 mg, given intravenously once a day for four days, followed by 25 mg NADH intramuscularly after 2 and 4 weeks
Number of subjects: 9

Group type: COMPARATOR
Intervention: Sodium chloride (control group)
Number of subjects: 9
Study: 3039130

Group type: EXPERIMENTAL
Intervention: Unprocessed bran 5 g three times daily
Number of subjects: 90

Group type: COMPARATOR
Intervention: Unprocessed bran 2.5 g three times daily
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo three times daily
Number of subjects: 90
Study: 31834410

Group type: COMPARATOR
Intervention: I‐MORE
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: I‐MORE+WI
Number of subjects: 175
Study: 29510998

Group type: EXPERIMENTAL
Intervention: Hypothermia (intensive care with cooling of the body to 33.5°C for 72 hours)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Control (intensive care alone)
Number of subjects: 145
Study: 28578607

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate plus prednisone (1000 mg daily, given once daily as four 250-mg tablets; prednisone 5 mg daily)
Number of subjects: 1199
Study: 26164097

Group type: EXPERIMENTAL
Intervention: Vaccination only
Number of subjects: 267270

Group type: EXPERIMENTAL
Intervention: Vaccination and behavioural change
Number of subjects: 267270

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 267270
Study: 23117775

Group type: EXPERIMENTAL
Intervention: Daily multivitamin
Number of subjects: 14641

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14641
Study: 21070998

Group type: EXPERIMENTAL
Intervention: 100 kVp protocol
Number of subjects: 400

Group type: COMPARATOR
Intervention: 120 kVp protocol
Number of subjects: 400
Study: 18172412

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle strength training (IMT) for 10 weeks
Number of subjects: 46

Group type: COMPARATOR
Intervention: Nontreatment control group
Number of subjects: 46
Study: 15879021

Group type: EXPERIMENTAL
Intervention: MenB/C
Number of subjects: 0

Group type: COMPARATOR
Intervention: MenBvac
Number of subjects: 0

Group type: COMPARATOR
Intervention: Menjugate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11932859

Group type: EXPERIMENTAL
Intervention: Frozen peas
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Flexible frozen gel pack
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study: 9800740

Group type: EXPERIMENTAL
Intervention: Tamoxifen (40 mg per day)
Number of subjects: 496

Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 496
Study: 8617576

Group type: EXPERIMENTAL
Intervention: Gallium nitrate
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Amonafide
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Teniposide
Number of subjects: 55
Study: 2548551

Group type: EXPERIMENTAL
Intervention: Cilazapril (4 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Captopril (25 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 132566

Group type: EXPERIMENTAL
Intervention: Ipratropiumbromide (30 mg or more)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propanthelinbromide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ipratropiumbromide + Oxacepam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oxacepam
Number of subjects: 0
Study: 31322583

Group type: EXPERIMENTAL
Intervention: Amplitude of motor evoked potentials of the extensor digitorum communis (EDC) muscle
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ability to voluntarily extend the fingers
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: MEP amplitudes of biceps brachii and adductor digiti minimi muscles
Number of subjects: 18
Study: 29699723

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg ketamine racemate
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 80
Study: 26937913

Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery (ERAS) program
Number of subjects: 187

Group type: COMPARATOR
Intervention: Control group (traditional care)
Number of subjects: 187
Study: 24509214

Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 1442

Group type: COMPARATOR
Intervention: Past smokers
Number of subjects: 1442

Group type: COMPARATOR
Intervention: Total cohort of patients
Number of subjects: 1442

Group type: COMPARATOR
Intervention: Patients with ischemic and nonischemic cardiomyopathy
Number of subjects: 1442
Study: 21316256

Group type: EXPERIMENTAL
Intervention: Primary closure of donor site (group 1)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Granulation of donor site (group 2)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both groups (group 1 and group 2)
Number of subjects: 15
Study: 20156055

Group type: EXPERIMENTAL
Intervention: Arm I: Isoniazid, rifampicin, and pyrazinamide simultaneously at full dosage from day 1
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Arm II: Drugs administered according to American Thoracic Society guidelines
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Arm III: Drugs administered according to British Thoracic Society guidelines
Number of subjects: 175
Study: 18030209

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement therapy (0.25 mg/kg subcutaneously each week)
Number of subjects: 24
Study: 15682323

Group type: EXPERIMENTAL
Intervention: Hyperoxia (FIO2 of 30%) during Moderate1
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Hyperoxia (FIO2 of 30%) during Moderate2
Number of subjects: 9

Group type: COMPARATOR
Intervention: Normoxia during Moderate1
Number of subjects: 9

Group type: COMPARATOR
Intervention: Normoxia during Moderate2
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Hyperoxia (FIO2 of 30%)
Number of subjects: 9
Study: 10222855

Group type: EXPERIMENTAL
Intervention: Teaching video for discharge preparatory teaching
Number of subjects: 59

Group type: COMPARATOR
Intervention: Standard teaching
Number of subjects: 59
Study: 7884421

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy regimen (cyclophosphamide 7.2 g/m2, carmustine 300 mg/m2 or 600 mg/m2, etoposide 2,400 mg/m2) followed by allogeneic bone marrow transplantation (allo BMT)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy regimen (carmustine 600 mg/m2)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy regimen (carmustine 300 mg/m2)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Allo BMT following high-dose CBV regimen
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Allo BMT for advanced disease
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Allo BMT
Number of subjects: 56
Study: 2102750

Group type: COMPARATOR
Intervention: Sustained-action nifedipine (NF)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Chlorthalidone (CL)
Number of subjects: 72
Study: 638577

Group type: EXPERIMENTAL
Intervention: Salbutamol 10 microgram/min
Number of subjects: 62

Group type: COMPARATOR
Intervention: Aminophylline 1 mg/min
Number of subjects: 62
Study: 31809413

Group type: EXPERIMENTAL
Intervention: Apnea
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31744484

Group type: EXPERIMENTAL
Intervention: Peer evaluation in pharmacodynamics items (PE-PD)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Peer evaluation in pharmacokinetics items (PE-PK)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Teachers' marks for oral presentation (PE-PD)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Teachers' marks for oral presentation (PE-PK)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Final examination marks (PE-PD)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Final examination marks (PE-PK)
Number of subjects: 72
Study: 28343757

Group type: EXPERIMENTAL
Intervention: IVF‐M HP
Number of subjects: 112

Group type: COMPARATOR
Intervention: Menopur
Number of subjects: 112
Study: 25645122

Group type: EXPERIMENTAL
Intervention: Integrated care (COPD-Home)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 172
Study: 23468158

Group type: EXPERIMENTAL
Intervention: Walking slowly (slower)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Walking with cueing at the BEFORE pace (metronome)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Walking without cueing at the BEFORE pace (normal)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Walking fast (faster)
Number of subjects: 48
Study: 20961772

Group type: EXPERIMENTAL
Intervention: Thoracoscopic talc poudrage (TTP)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Povidone‐iodine pleurodesis (PIP)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both groups (TTP and PIP)
Number of subjects: 42
Study: 20146877

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg twice a day (bid)
Number of subjects: 1598

Group type: COMPARATOR
Intervention: Tramadol HCl 50 mg four times a day (qid)
Number of subjects: 1598

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg bid
Number of subjects: 1598
Study: 17579709

Group type: EXPERIMENTAL
Intervention: Decision protocol for identifying obesity risk
Number of subjects: 5778

Group type: COMPARATOR
Intervention: Non-selected peers
Number of subjects: 5778
Study: 16321614

Group type: EXPERIMENTAL
Intervention: Bradykinin B(2) receptor antagonist HOE 140 (100 mug/kg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 16
Study: 12029261

Group type: EXPERIMENTAL
Intervention: Antithrombin III (ATIII) administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Heparin (concomitant use)
Number of subjects: 0
Study: 9534634

Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Different definitions of hypotension and baseline measurements
Number of subjects: 20
Study: 8042462

Group type: EXPERIMENTAL
Intervention: Pad with traditional cellulose absorbent core
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pad containing cellulose and absorbent gelling material
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-pad control period
Number of subjects: 0
Study: 2639195

Group type: EXPERIMENTAL
Intervention: 0.1% chlorhexidine mouthrinse
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo mouthrinse
Number of subjects: 40
Study: 1097207

Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 36
Study: 30421441

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) bolus of cangrelor (30 μg/kg) followed by a 120‐minute infusion (4 μg/kg/min)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Matching saline placebo
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 210
Study: 28285041

Group type: EXPERIMENTAL
Intervention: Infants playing alone for 2 minutes
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Infants playing with a caregiver for 2 minutes
Number of subjects: 76
Study: 26066622

Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 167

Group type: COMPARATOR
Intervention: Donepezil (Control)
Number of subjects: 167
Study: 23125443

Group type: EXPERIMENTAL
Intervention: Ad26.ENVA.01 vaccine
Number of subjects: 0
Study: 21652072

Group type: EXPERIMENTAL
Intervention: School-based violence prevention program (21 lessons of 75 minutes each)
Number of subjects: 1722

Group type: COMPARATOR
Intervention: Non-intervention schools
Number of subjects: 1722
Study: 19454921

Group type: EXPERIMENTAL
Intervention: Media literacy program
Number of subjects: 540

Group type: COMPARATOR
Intervention: Control (normal school lessons)
Number of subjects: 540
Study: 16734961

Group type: EXPERIMENTAL
Intervention: Standard partner letter and website
Number of subjects: 105

Group type: COMPARATOR
Intervention: Standard partner letter
Number of subjects: 105
Study: 15229389

Group type: EXPERIMENTAL
Intervention: Aspirin plus cilostazol
Number of subjects: 5

Group type: COMPARATOR
Intervention: Aspirin plus ticlopidine
Number of subjects: 5
Study: 11358941

Group type: EXPERIMENTAL
Intervention: Adrenomedullin high dose (5.8 pmol/kg per minute)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Adrenomedullin low dose (2.9 pmol/kg per minute)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Vehicle control (Hemaccel)
Number of subjects: 8
Study: 9433365

Group type: EXPERIMENTAL
Intervention: Continuous administration of 10 mg cetirizine daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: On demand treatment with cetirizine
Number of subjects: 20
Study: 8357678

Group type: EXPERIMENTAL
Intervention: Topical prostaglandin E2 (PGE2) gel at a dose of 0.3 mg twice daily for 10 days
Number of subjects: 35

Group type: COMPARATOR
Intervention: Vehicle alone (placebo)
Number of subjects: 35
Study: 3693870

Group type: EXPERIMENTAL
Intervention: Individualized dose of amitriptyline calculated by a pharmacokinetic test
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fixed dose of amitriptyline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individualized dose of amitriptyline
Number of subjects: 0
Study: 28966061

Group type: EXPERIMENTAL
Intervention: Surgical treatment (suture anchor technique)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 29
Study: 27513650

Group type: EXPERIMENTAL
Intervention: Supine Bicycle (SB)
Number of subjects: 12
Study: 25402210

Group type: EXPERIMENTAL
Intervention: Natural images
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Urban with nature environments
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Built‐up without nature environments
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Built‐up without nature environments with striking architectural qualities
Number of subjects: 104
Study: 23368420

Group type: EXPERIMENTAL
Intervention: Greater perceived control of asthma
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Increased anxiety
Number of subjects: 175